BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26738784)

  • 1. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
    Luo YY; Tao Y; Cai XF; Zhang WL; Long QX; Guo H; Huang AL; Hu JL
    Antiviral Res; 2016 Feb; 126():99-107. PubMed ID: 26738784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
    Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
    J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
    Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
    Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
    Su F; Dai J; Yang S; Jiang X; Cui X; Ning H; Li J; Huang M
    J Med Virol; 2015 Sep; 87(9):1527-31. PubMed ID: 26032700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
    Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E
    J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV mutations associated with lamivudine therapy.
    Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
    Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
    Gomes-Gouvêa MS; Ferreira AC; Teixeira R; Andrade JR; Ferreira AS; Barros LM; Rezende RE; Nastri AC; Leite AG; Piccoli LZ; Galvan J; Conde SR; Soares MC; Kliemann DA; Bertolini DA; Kunyoshi AS; Lyra AC; Oikawa MK; de Araújo LV; Carrilho FJ; Mendes-Corrêa MC; Pinho JR
    Antivir Ther; 2015; 20(4):387-95. PubMed ID: 25624410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs.
    Xiang KH; Zhao CY; Wang S; Li Y; Su MZ; Wang QY; Xu XZ; Deng J; Zhuang H; Li T
    Antivir Ther; 2018; 23(1):33-42. PubMed ID: 28440785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
    Shirvani-Dastgerdi E; Winer BY; Celià-Terrassa T; Kang Y; Tabernero D; Yagmur E; Rodríguez-Frías F; Gregori J; Luedde T; Trautwein C; Ploss A; Tacke F
    J Hepatol; 2017 Aug; 67(2):246-254. PubMed ID: 28392234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
    Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
    J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
    Tenney DJ; Rose RE; Baldick CJ; Levine SM; Pokornowski KA; Walsh AW; Fang J; Yu CF; Zhang S; Mazzucco CE; Eggers B; Hsu M; Plym MJ; Poundstone P; Yang J; Colonno RJ
    Antimicrob Agents Chemother; 2007 Mar; 51(3):902-11. PubMed ID: 17178796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
    Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
    J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.